FDA, Lilly
Eli Lilly’s weight-loss and diabetes drugs are no longer in shortage, says FDA
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in expanding manufacturing.
England's NHS to offer Lilly's weight-loss drugs to some patients
England's National Health Services plans to offer Eli Lilly's weight-loss drugs to nearly a quarter million people as part of a three-year plan, UK's drugs cost regulator said on Thursday.
Lilly’s Tirzepatide No Longer on FDA Drug Shortage List
BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, which is growing market share in incretin products as manufacturing continues to expand, while noting the drugmaker could start to benefit heading into third quarter earnings.
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.
Eli Lilly GLP-1 shortage officially ends, hurting Hims & Hers
FDA announces Eli Lilly's Tirzepatide is no longer in shortage in the US. Impact on compounded GLP-1s & semaglutide supply.
Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List
Shares in Hims & Hers Health fell after the U.S. Food and Drug Administration said Eli Lilly's obesity and diabetes drugs are no longer in shortage. Shares were down 7% in premarket trading to $17.64.
Eli Lilly’s Weight-Loss Drugs No Longer In Shortage. It’s Bad News for These Stocks.
Eli Lilly’s blockbuster obesity and diabetes drugs Zepbound and Mounjaro are no longer in shortage, according to the Food and Drug Administration. It’s a sign that the pharmaceutical giant is making strides to improve the supply issues that have plagued the sector.
Lilly's weight-loss drug removed from FDA's shortage list
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list ...
This IPO Biotech Stock Could Be the Next Eli Lilly
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Drugmaker Lilly Slates Another $4.5B for Manufacturing and Drug Development Improvements
Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve ...
Lilly to invest $4.5 bln on new facility to scale-up pipeline drug production
U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and ...
Daily Journal1h
Lilly to invest another $4.5B in Lebanon site for new ‘medicine foundry’
The new funding will bring the Indianapolis-based drugmaker’s total investment in the Lebanon site to more than $13 billion, ...
England’s NHS to Offer Eli Lilly Obesity Drug to Some Patients
Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years ...
Eli Lilly to build $4.5 billion Indiana facility for advanced drug manufacturing
Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...